文献速递慢阻肺

慢阻肺的自然史与机制

Natural history and mechanisms of COPD.
PubMed 文献 · Respirology · 2021-01-28

本文综述慢阻肺的自然史与机制。慢阻肺是生命周期中多因素交互作用的综合征,吸烟是最强诱因。诊断常延迟,存在长期临床前期。肺功能轨迹可分两类:成年早期达正常最大肺功能后FEV1加速下降,或最大肺功能低于正常。持续吸烟与疾病进展、结构性疾病和不良预后相关。机制涉及结构和炎症改变,小气道上皮可能是关键部位。

要点

  • 慢阻肺诊断常延迟,存在长期临床前期。
  • 肺功能轨迹分两类:最大肺功能正常后加速下降,或最大肺功能低于正常。
  • 持续吸烟与疾病进展、结构性疾病和不良预后相关。

核心结论

  • 慢阻肺是生命周期中多因素交互作用的综合征,吸烟是最强诱因。
  • 不同表型患者自然史不同,肺功能轨迹可分两类。
  • 持续吸烟与疾病进展、结构性疾病和不良预后相关。
  • 小气道上皮可能是疾病关键部位,涉及上皮-间质交互和结构/炎症改变。

研究设计与样本

  • 综述,总结关于慢阻肺发展与进展的最新研究,聚焦肺功能轨迹、急性加重和生存。
  • 综述机制,聚焦慢阻肺相关上皮改变和炎症过程消退不足。

主要发现

  • 诊断常延迟,纵向队列研究揭示长期临床前期。
  • 肺功能轨迹两类:成年早期最大肺功能正常后FEV1加速下降;或最大肺功能低于正常而成年期FEV1下降正常或略快。
  • 持续吸烟与疾病进展、结构性疾病和不良预后强相关。
  • 发展中国家生物质暴露和结核后遗症可能导致更以气道为中心的慢阻肺表型。
  • 病理可见上皮化生、杯状细胞与纤毛细胞比例倒置、黏膜下腺增大、中性粒细胞和CD8-T细胞浸润。

临床怎么用

  • 关注肺功能轨迹,早期识别最大肺功能低于正常或FEV1加速下降个体。
  • 强调持续吸烟与不良预后相关,戒烟重要。
  • 小气道上皮和炎症消退不足可能是治疗靶点,2型炎症和警报素生物学受关注。

局限性

  • 小气道水平慢阻肺进展临床难以察觉,病理过程描述不足。
  • 哮喘特征可能增加混淆。
  • 患者表型异质性大,机制可能不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The natural history of COPD is complex, and the disease is best understood as a syndrome resulting from numerous interacting factors throughout the life cycle with smoking being the strongest inciting feature. Unfortunately, diagnosis is often delayed with several longitudinal cohort studies shedding light on the long 'preclinical' period of COPD. It is now accepted that individuals presenting with different COPD phenotypes may experience varying natural history of their disease. This includes its inception, early stages and progression to established disease. Several scenarios regarding lung function course are possible, but it may conceptually be helpful to distinguish between individuals with normal maximally attained lung function in their early adulthood who thereafter experience faster than normal FEV1 decline, and those who may achieve a lower than normal maximally attained lung function. This may be the main mechanism behind COPD in the latter group, as the decline in FEV1 during their adult life may be normal or only slightly faster than normal. Regardless of the FEV1 trajectory, continuous smoking is strongly associated with disease progression, development of structural lung disease and poor prognosis. In developing countries, factors such as exposure to biomass and sequelae after tuberculosis may lead to a more airway-centred COPD phenotype than seen in smokers. Mechanistically, COPD is characterized by a combination of structural and inflammatory changes. It is unlikely that all patients share the same individual or combined mechanisms given the heterogeneity of resultant phenotypes. Lung explants, bronchial biopsies and other tissue studies have revealed important features. At the small airway level, progression of COPD is clinically imperceptible, and the pathological course of the disease is poorly described. Asthmatic features can further add confusion. However, the small airway epithelium is likely to represent a key focus of the disease, combining impaired subepithelial crosstalk and structural/inflammatory changes. Insufficient resolution of inflammatory processes may facilitate these changes. Pathologically, epithelial metaplasia, inversion of the goblet to ciliated cell ratio, enlargement of the submucosal glands and neutrophil and CD8-T-cell infiltration can be detected. Evidence of type 2 inflammation is gaining interest in the light of new therapeutic agents. Alarmin biology is a promising area that may permit control of inflammation and partial reversal of structural changes in COPD. Here, we review the latest work describing the development and progression of COPD with a focus on lung function trajectories, exacerbations and survival. We also review mechanisms focusing on epithelial changes associated with COPD and lack of resolution characterizing the underlying inflammatory processes.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Lange P, Ahmed E, Lahmar ZM, et al. Natural history and mechanisms of COPD. Respirology. 2021. PMID: 33506971. doi:10.1111/resp.14007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。